This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Icagen CEO Discusses Q4 2010 Results - Earnings Call Transcript

Icagen, Inc. (ICGN)

Q4 2010 Earnings Conference Call

March 7, 2011 10:00 am ET

Executives

Richard Katz - Executive Vice President and Chief Financial Officer

Kay Wagoner - Chief Executive Officer

Analysts

Christopher James - McNicoll, Lewis & Vlak

Dominique Sémon - Merlin Nexus

Chris Richard - Merlin Nexus

Tore Steen - Anthem Funds

Presentation

Operator

Good day, ladies and gentlemen and welcome to the Fourth Quarter 2010 Icagen Incorporated Earnings Conference Call. My name is Dazzman [ph] and I’ll be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. (Operator Instructions).

I would now like to turn the conference over to your host to Dr. Richard Katz, Executive Vice President and Chief Financial Officer. Please proceed.

Richard Katz - Executive Vice President and Chief Financial Officer:

Thank you very much operator. Good morning everyone. Thanks for joining us today to discuss Icagen’s corporate research and clinical progress as well as our financial results for the fourth quarter and the yearend. With me here today is Kay Wagoner, our CEO and Greg Rigdon, our Head of New Product Development. Kay will start the call today with a general overview. I will then address the financial results and Greg will be available to answer questions as well.

Before we begin, I would just like to read the following regarding any forward-looking statements that we may make today. Various remarks that we may make about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from these forward-looking statements as a result of various important factors, including those discussed in our most recent quarterly report as filed with the SEC.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs